– CANADA, Toronto – FSD Pharma Inc. (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company, today announced the appointment of Co-Founder and Executive Co-Chairman Zeeshan Saeed as CEO, effective on June 29, 2023, succeeding his fellow Co-Founder Anthony Durkacz, who has been serving as the Interim CEO since July 2021.
Mr. Durkacz and Mr. Saeed will continue to hold their positions as Executive Co-Chairman of the Board of Directors.
About FSD Pharma
FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for potentially quickly relieving the effects of alcohol consumption, such as inebriation, and restoring a normal lifestyle.
For more information: https://fsdpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
